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A B S T R A C T
The ability to generate patient-specific induced pluripotent stem cells (iPSCs) provides a unique opportunity for
modeling heart disease in vitro. In this study, we generated iPSCs from a patient with dilated cardiomyopathy
(DCM) caused by a missense mutation S635A in RNA-binding motif protein 20 (RBM20) and investigated the
functionality and cell biology of cardiomyocytes (CMs) derived from patient-specific iPSCs (RBM20-iPSCs). The
RBM20-iPSC-CMs showed abnormal distribution of sarcomeric α-actinin and defective calcium handling com-
pared to control-iPSC-CMs, suggesting disorganized myofilament structure and altered calcium machinery in
CMs of the RBM20 patient. Engineered heart muscles (EHMs) from RBM20-iPSC-CMs showed that not only
active force generation was impaired in RBM20-EHMs but also passive stress of the tissue was decreased, sug-
gesting a higher visco-elasticity of RBM20-EHMs. Furthermore, we observed a reduced titin (TTN) N2B-isoform
expression in RBM20-iPSC-CMs by demonstrating a reduction of exon skipping in the PEVK region of TTN and an
inhibition of TTN isoform switch. In contrast, in control-iPSC-CMs both TTN isoforms N2B and N2BA were
expressed, indicating that the TTN isoform switch occurs already during early cardiogenesis. Using next gen-
eration RNA sequencing, we mapped transcriptome and splicing target profiles of RBM20-iPSC-CMs and iden-
tified different cardiac gene networks in response to the analyzed RBM20 mutation in cardiac-specific processes.
These findings shed the first light on molecular mechanisms of RBM20-dependent pathological cardiac re-
modeling leading to DCM. Our data demonstrate that iPSC-CMs coupled with EHMs provide a powerful tool for
evaluating disease-relevant functional defects and for a deeper mechanistic understanding of alternative spli-
cing-related cardiac diseases.
1. Introduction
Dilated cardiomyopathy (DCM) is a major cause of cardiovascular
mortality, which is due to a progressive enlargement of the heart
leading finally to heart failure. Only recently alternative splicing related
cardiovascular diseases have been described [1]. RBM20 codes for the
http://dx.doi.org/10.1016/j.yjmcc.2017.09.008
Received 9 April 2017; Received in revised form 1 September 2017; Accepted 19 September 2017
⁎ Corresponding author at: Institute of Pharmacology and Toxicology, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
E-mail address: kaomei.guan@tu-dresden.de (K. Guan).
Journal of Molecular and Cellular Cardiology 113 (2017) 9–21
Available online 21 September 2017
0022-2828/ © 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
splicing factor RNA-binding motif protein 20 that contains two evolu-
tionary highly conserved functional domains: a RNA-recognition motif
1 (RRM-1) and an arginine/serine-rich (RS-rich) domain. RBM20 plays
an important role in assembling spliceosome and regulating alternative
splicing of pre-mRNA [2–4]. Several heterozygous missense mutations
in RBM20 including R634Q, R634W, S635A, R636S, R636H, R636C,
S637G and P638L, which cause early-onset DCM, were identified in a
five amino acid hotspot in the RS-rich domain [2,5–8]. RBM20 muta-
tions exist in up to 3% of patients with idiopathic DCM, in 5% of
confirmed or suspected familial cases and in over 13% of patients with a
history of sudden cardiac death. These mutations are associated with a
younger age at diagnosis, end-stage heart failure, and a high degree of
morbidity and mortality [5,6,8].
RBM20 was identified as the first splicing factor of the sarcomeric
protein titin (TTN), a main determinant of diastolic function [2]. Rats
with a deletion of exons 2–14 of Rbm20 revealed many phenotypic
features that are observed in patients with DCM related to mutant
RBM20 [2]. Besides TTN, a set of 30 genes with conserved alternative
splicing regulation between humans and rats were identified to be in-
volved in Rbm20-dependent alternative splicing processes, including
genes linked to cardiomyopathy, ion-homeostasis, and sarcomere
biology [2]. A Rbm20-knockdown study in mouse embryonic stem cells
(ESCs) showed that Rbm20 deficiency in ESC-derived cardiomyocytes
(CMs) resulted in impaired sarcomere organization and ion transport in
the sarcoplasmic reticulum, coinciding with early disruption of RNA
processing [9].
A big hurdle for understanding cardiac molecular and cellular
physiology is the general unfeasibility to maintain and study functional
human CMs in culture. Given the ability to generate and cultivate
human induced pluripotent stem cells (iPSCs) in vitro, patient-specific
iPSC-derived CMs (iPSC-CMs) provide a unique opportunity to model
heart diseases in vitro [10,11].
Here, we hypothesized that iPSC-CMs derived from a DCM patient
with the missense mutation S635A in the conserved RS-rich domain of
RBM20 can be used to investigate the pathogenesis of mutant RBM20-
causing DCM at cellular and molecular levels. We generated engineered
heart muscles (EHMs) from iPSC-CMs and studied their active and
passive force generation. The functionality and cell biology of these
patient-specific iPSC-CMs as well as EHMs, specifically those related to
the cardiac DCM phenotype, would give novel insights into the func-
tional changes during DCM development. Furthermore, splicing factors
as RBM20 are attractive targets to develop novel therapeutic and pro-
tective strategies on a patient-specific level.
2. Materials and methods
2.1. Patient
The study was approved by the ethical committee of the University
Medical Center Göttingen (Az. 21/1/11). A 34-year-old woman char-
acterized by severe DCM and arrhythmias was recruited in this study.
The female patient had an early onset of disease at the age of 23 years.
Because of syncope and arrhythmias, an automated cardioverter-defi-
brillator was implanted. At the age of 29 years, she showed a severe
symptomatic heart failure (NYHA III). Echocardiographic examination
revealed left ventricular dilation with cardiac dysfunction (ejection
fraction about 29%). Genetic analysis revealed a heterozygous missense
mutation (S635A) in exon 9 of the RBM20 gene in the patient, as de-
scribed earlier [2].
2.2. Isolation and cultivation of skin fibroblasts
For the establishment of skin fibroblast culture, skin punch biopsies
(3.5–4 mm) were taken aseptically by a surgeon, placed in Dulbecco's
modified Eagle's medium (DMEM; Thermo Fisher Scientific) containing
penicillin (100 U/ml)/streptomycin (100 μg/ml) (Thermo Fisher
Scientific), transferred as soon as possible to the lab and cut into pieces
of 1–1.5 mm side length. The pieces were then placed epidermis upside
in cell culture dish and cultured in fibroblast growth medium composed
of DMEM supplemented with 10% fetal calf serum (FCS; selected batch,
Lonza), 1× non-essential amino acids (NEAA; Thermo Fisher
Scientific), glutamine (2 mM; Thermo Fisher Scientific), β-mercap-
toethanol (β-ME; 50 μM, Promega), penicillin (50 U/ml)/streptomycin
(50 μg/ml) at 37 °C with 5% CO2 atmosphere without moving the
dishes. Fibroblasts grew out from the tissue pieces and were passaged
two weeks later. The cells are normally ready for transduction experi-
ments before passage 3 (p3).
2.3. Generation, culture and characterization of hiPSCs
Generally, a total of 2–3 × 104 fibroblasts from the patient (F-1-
RBM20; F-1-R) plated in fibroblast growth medium in one well of a 6-
well tissue culture plate were transduced with lentiviral particles as
described before [12]. As lentiviral system the STEMCCA cassette was
used, which is a humanized excisable system containing all four re-
programming factors OCT4, SOX2, KLF4, and c-MYC in a single “stem
cell cassette” (pHAGE2-EF1αFull-hOct4-F2A-hKlf4-IRES-hSox2-P2A-
hcMyc-W-loxP) [12]. The generated iPSCs were cultured on mitomycin
C-inactivated mouse embryonic fibroblasts and propagated by using
collagenase IV (200 U/ml, Worthington) in human ESC medium as
described previously [12].
For characterization of the generated iPSCs regarding their plur-
ipotency, RT-PCR analysis, immunocytochemical staining, bisulfite se-
quencing assays, spontaneous differentiation in vitro and teratoma for-
mation in vivo were carried out using standard protocols as described
earlier [12]. For details, please see Supplementary data.
Three independent iPSC lines derived from the patient were desig-
nated 1-RBM20-2 (1-R-2), -3 (1-R-3), -7 (1-R-7) (Table S1), character-
ized for their pluripotency and used in this study. As healthy controls,
we used five iPSC lines derived from three healthy donors without
known cardiovascular diseases (designated C1-1, C1-2, C2-1, C2-2 and
C3-1, respectively) (Table S1).
2.4. Directed differentiation of iPSCs into cardiomyocytes
The generated iPSC lines were adapted from feeder-dependent cul-
tures to feeder-free adherent cultures by cultivating on Geltrex-coated
cell culture plates in the presence of chemically defined medium E8
(Thermo Fisher Scientific). Cardiac differentiation of iPSCs was per-
formed by sequential targeting of the Wnt pathway as described pre-
viously [13]. Briefly, undifferentiated iPSCs were cultured as a mono-
layer in E8 medium on Geltrex-coated 12-well plates. At 85%–95%
confluence, the differentiation was initiated by changing the medium to
RPMI 1640 (Thermo Fisher Scientific) supplemented with 2 mM L-glu-
tamine, 1× B27 without insulin (Thermo Fisher Scientific) and the
GSK3β inhibitor CHIR99021 (10 μM, Millipore) (d0). After 48 h,
medium was changed to fresh media supplemented with 5 mM of the
Wnt signaling inhibitor IWP2 (Millipore) for two days. From day 8 on,
the cells were cultured in cardio culture medium containing RPMI 1640
supplemented with 2 mM L-glutamine and 1× B27 with insulin
(Thermo Fisher Scientific), with a medium change every 2–3 days. CMs
were purified using metabolic selection [14] and studied on day 60
after initiation of differentiation except when mentioned otherwise.
2.5. Surface area measurement of iPSC-CMs
On day 60 after differentiation, the single iPSC-CMs were im-
munostained with antibodies against α-actinin, cardiac troponin T
(cTNT), and ventricular isoform of the myosin light chain 2 (MLC2V),
and images were made using a fluorescence microscope (Zeiss Observer
Z1). The surface areas of the single iPSC-CMs were measured by using
computerized morphometric system (ImageJ software, NIH Bethesda).
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2.6. Measurement of sarcomeric regularity in iPSC-CMs
Images of single iPSC-CMs stained for α-actinin were processed by a
custom routine in ImageJ for quantitative analysis of sarcomere orga-
nization. To get proper measurements of sarcomere organization, the
striation pattern of the α-actinin staining was first aligned vertically
within the field of view. The sarcomere organization was quantitated
from a user-defined region of interest (ROI) with sarcomeres. The 2D
fast Fourier transform (FFT) of images was processed as described
previously [15] for un-patterned images, the 2D Fourier spectra were
converted to 1D representations by summing up the radial profiles of
the 2D FFT resulting in a series of peaks localized at integer multiples of
the spatial frequency of the sarcomeric pattern. The amplitude of the
first-order peak is a measure of sarcomere regularity, as the organiza-
tion increases as more sarcomeric α-actinin-positive elements are lo-
calized regularly at a distance of the sarcomere length [15].
2.7. Measurement of calcium transients in iPSC-CMs
For intracellular Ca2+ transient recordings, both control- and
RBM20-iPSC-CMs around day 60 were digested, plated on Geltrex-
coated glass coverslips and incubated in cardio culture medium for one
week before use. For Ca2+ imaging, iPSC-CMs were first incubated with
5 μM Fura-2-AM (Thermo Fisher Scientific) for 30 min. Following in-
cubation, cells were washed once and incubated in cardio culture
medium for additional 15 min before measurements were started to
enable complete de-esterification of intracellular Fura-2 and allow
cellular rebalance of Ca2+ cycling properties. Intracellular Ca2+ tran-
sients in spontaneously beating control- and RBM20-iPSC-CMs were
recorded using an IonOptix system (Milton, MA) at 35 °C. Cells were
excited at 340 and 380 nm and the emitted fluorescence was collected
at 510 nm. The intracellular Ca2+ level was measured as the ratio of
fluorescence at 340 and 380 nm (340/380 nm). Analysis included the
peak amplitude (the Fura-2 ratio at systole subtracted by the Fura-2
ratio at diastole) of Ca2+ transients, the area under the curve of Ca2+
transients, time to peak, the rising slope, the decay rate (Tau) of Ca2+
transients, the duration and the frequency of Ca2+ transients. Data files
were exported and monotonic transient analysis was performed with
the software LabChart Pro (ADInstruments).
2.8. Western blot
For analysis of TTN-isoform composition, pellets of iPSC-CMs or
small pieces of left ventricular tissue from an adult human non-failing
heart that did not carry any non-synonymous sequence variants in
RBM20 were solubilized in a modified Laemmli buffer (8 M Urea, 2 M
thiourea, 3% SDS (w/v), 75 mM DTT, 0.03% (w/v) bromophenol blue,
10% (v/v) glycerol, 50 mM Tris-HCl, pH 6.8). Frozen myocardial
sample originated from a healthy donor heart that could not be trans-
planted for technical reasons. The human sample was achieved in
compliance with the local ethical committee (Az. 31/9/00), and written
informed consent was received from the participant before inclusion.
Titin isoforms were separated on agarose-strengthened SDS-poly-
acrylamide gels (1.8% polyacrylamide, 0.5% agarose) and analyzed as
previously described [16]. Protein bands on polyvinylidene difluoride
(PVDF) membranes were visualized with Coomassie brilliant blue R.
For immuno-detection, antibodies against the N- and C-terminal frag-
ments of titin (Myomedix) were used. ImageJ software was used for
densitometry analyses of titin gels and immunoblots.
2.9. Generation and functional phenotyping of engineered heart muscles
Circular EHMs were generated according to the previously pub-
lished protocol [17,18]. Briefly, 4-week-old beating control- and
RBM20-iPSC-CMs (1 × 106/EHM) with the estimated purity in a range
of 65% - 80% were selected and mixed carefully on ice with bovine
collagen type I (Collagen Solutions LLC) and EHM medium (Iscove's
modified Dulbecco's medium, 2 mM L-glutamine, 20% FCS, 1× NEAA,
0.1 mM β-ME, penicillin (100 U/ml)/streptomycin (100 μg/ml), all
from Thermo Fisher Scientific) and then casted into circular molds
(inner/outer diameter: 4/8 mm; height: 5 mm; volume: 450 μl). The
purity of iPSC-CMs was exemplarily determined by flow cytometry
analysis using the antibody against α-actinin. After a 3-day condensa-
tion phase, EHMs were transferred onto mechanical stretchers for
continuous culture under auxotonic strain and for functional matura-
tion for additional 12–14 days. Culture medium was changed 24 h after
EHM casting and then every other day.
Active force generation of EHMs was measured under isometric
conditions in continuously gassed (5% CO2/95% O2) Tyrode's solution
(containing: 120 mM NaCl, 1 mM MgCl2, 0.2 mM CaCl2, 5.4 mM KCl,
22.6 mM NaHCO3, 4.2 mM NaH2PO4, 5.6 mM glucose, and 0.56 mM
ascorbate). Then a calcium response curve (0.2–4 mM) and stimulation
with isoprenaline (1 μM) at half-maximal calcium concentration (EC50)
was performed. Passive forces (stress) were recorded as approximation
of stiffness by stepwise increasing EHM length (strain) to length of
maximal force development at stimulation frequency of 1.5 Hz (field
stimulation, pulse width 5 ms, voltage 10% above threshold) and 2 mM
calcium concentration. Volume or size measurement of CMs in EHMs
was performed by using flow cytometry after the digestion of EHMs into
single cells [18]. To measure cross-sectional area (CSA) of EHMs, pic-
tures of each EHM were taken from the frontal and side views while
suspended in the organ bath. An average of three readings of frontal
width (FW) and side width (SW) of each EHM arm were taken and CSA
was calculated according to the following formula: CSA = FW/
2 × SW/2 × π× 2.
2.10. RNA sequencing (RNA-seq) and bioinformatics
Differential gene expression was obtained by use of RNA sequencing
performed on an Illumina HighSeq-2000 platform and bioinformatics.
Total RNA was isolated from 2-month-old iPSC-CMs from 2 controls
with 2 cell lines each (n = 6 samples) and from 2 RBM20-iPSC lines
(n = 3 samples) using standard protocols (Promega). 150 ng RNA per
sample was subjected to library preparation (TruSeq RNA Library Prep
Kit v2, Illumina) and next-generation RNA sequencing using paired-end
sequencing (2 × 75 bp,> 40 Mio reads/sample) by the application of
Illumina HiSeq2000 platform.
The analysis of RNA-seq data was performed as described previously
[19]. In brief, RNA-seq data were aligned to the genome using gapped
alignment as RNA transcripts are subject to splicing and reads might
therefore span two distant exons. Reads were aligned to the whole homo
sapiens hg19 genome using STAR aligner (2.3.0e_r291) with default
options, generating mapping files (BAM format). Read counts for all
genes and all exons (Ensembl annotation v74) were obtained using
FeaturesCount (http://bioinf.wehi.edu.au/featureCounts/). Read
counts for differentially expressed genes (DEGs) were generated and the
samples from different groups were compared using DESeq2 [20].
Genes with a Benjamin and Hochberg–adjusted P value (false discovery
rate) of< 0.05 were considered to be differentially expressed. Read
counts for differentially expressed exons (DEEs) or differential exon
usage were generated and the samples from different groups were
compared using DEXSeq. Exons with an adjusted P value< 0.1 were
considered to be differentially expressed. Gene ontology (GO) enrich-
ment analysis of bioprocesses was performed with GOSeq [21].
2.11. Statistical analysis
To compare sarcomeric structure, cell surface area, Ca2+ transient
properties, TTN alternative splicing and gene expression, data that
passed tests for normality were analyzed with the use of Student's t-test.
Two-sided P values of< 0.05 were considered statistically significant.
For comparison of force of contraction and stress strain curve of EHMs,
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the two-way ANOVA was used. The statistical software used for analysis
was Graph pad prism (version 6). All data are reported as means±
standard error of the mean (SEM).
3. Results
3.1. Generation of patient-specific iPSC lines
We derived iPSCs from dermal fibroblasts (F-1-R) of the patient with
the heterozygous S635A mutation in RBM20. Three independent
RBM20-iPSC lines (1-R-2, -3, and -7) were generated and analyzed for
their pluripotency. They showed the typical human pluripotent stem
cell morphology and were positive for alkaline phosphatase (ALP;
Fig. 1A). DNA sequencing confirmed the expected mutation in the
generated RBM20-iPSC lines (Fig. 1B). RT-PCR analysis showed that
RBM20-iPSCs, similar to human ESCs (HES3), expressed pluripotency
markers like OCT4, NANOG, LIN28, and SOX2 (Fig. S1A) and bisulfite
sequencing revealed more demethylated promoter regions of OCT4 and
NANOG in the generated RBM20-iPSC lines compared to their parental
fibroblasts (Fig. 1C). In addition, all RBM20-iPSC lines were positive for
human pluripotent stem cell markers NANOG, OCT4, TRA-1-60, LIN28,
SSEA4, and SOX2 as demonstrated by immunocytochemical staining
(Fig. 1A). Differentiation potential of each RBM20-iPSC line was tested
in vitro via embryoid body (EB)-mediated differentiation (Figs. 1D, S1B)
and in vivo via teratoma formation (Fig. 1E). All RBM20-iPSC lines
differentiated into derivatives of three embryonic germ layers in vitro,
as detected by expression of genes specific for mesoderm, α-myosin
heavy chain (MYH6) and MLC2V, for endoderm, α-fetoprotein (AFP)
and albumin (ALB), and for neuroectoderm, tyrosine hydroxylase (TH)
(Fig. S1B). On protein level, smooth muscle α-actin (α-SMA) for
Fig. 1. Proof of pluripotency and spontaneous differentia-
tion capacity of RBM20-iPSCs. A, the generated RBM20-
iPSC lines with typical morphology for human pluripotent
stem cells expressed alkaline phosphatase (ALP) and were
positive for pluripotency markers NANOG, OCT4, TRA-1-
60, LIN28, SSEA4, and SOX2 as demonstrated by im-
munofluorescence staining. The cells were counterstained
with DAPI (blue). Scale bars, 100 μm. B, the expected
RBM20 mutation leading to the amino acid substitutions
S635A was confirmed in the generated iPSCs by DNA se-
quencing. C, bisulfite sequencing analysis of DNA methy-
lation of OCT4 and NANOG promoter regions. Color codes
indicate 0% (yellow), over 50% (green) to 100% (blue)
methylation. The y-axis shows individual CpGs analyzed.
The x-axis shows different cell types analyzed. HES3 was
used as a positive control. F-1-R are fibroblasts from the
RBM20 patient before reprogramming. All other cell lines
are iPSCs from the patient. D, immunofluorescence staining
of in vitro differentiated cells from RBM20-iPSCs using an-
tibodies against tissue-specific markers α-SMA (mesoderm),
AFP (endoderm), and β-III-tubulin (ectoderm). The cells
were counterstained with DAPI (blue). Scale bar, 100 μm.
E, teratoma formation of RBM20-iPSCs in immunodeficient
mice. Shown are striated muscles (mesoderm), epithelium
with intestinal differentiation (endoderm), and neural tis-
sues (ectoderm). Scale bar, 50 μm. (A, D, E) Shown are
representative images for one cell line of the RBM20 pa-
tient.
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mesodermal tissue, AFP for endodermal and β-III-tubulin for ecto-
dermal tissue were detected (Fig. 1D). Teratoma formation in im-
munodeficient mice (RAG2−/−γc−/−) confirmed in vivo differentiation
potential of the generated RBM20-iPSC lines by showing striated
muscles (mesoderm), epithelium with intestinal differentiation (en-
doderm), and neural tissues (ectoderm) (Fig. 1E).
3.2. RBM20-iPSC-CMs exhibit an increased heterogeneous sarcomeric
organization pattern but show no difference in cell size
The findings of cardiac-specific pathology of RBM20 deficiency [2]
caused our interest in studying the pathogenesis of RBM20 DCM using
RBM20-iPSC-CMs. Both control- and RBM20-iPSCs were differentiated
into CMs (Videos S1) with a purity of> 90% using a standardized
protocol [13,14]. Single beating CMs were used for further analysis. We
did not observe significant differences in cardiac differentiation capa-
city between control- and RBM20-iPSCs. The iPSC-CMs from both
control and the RBM20 patient expressed high levels of cardiac-specific
genes such as ACTN2, MYH6, MYH7, and TNNT2 whereas the expres-
sion of pluripotency genes (SOX2, and LIN28) was decreased (Fig. S2).
In addition, both control- and RBM20-iPSC-CMs expressed the sarco-
meric proteins α-actinin, cTNT as well as myosin light chain 2a
(MLC2A) and MLC2V (Fig. 2A). However, compared to control-iPSC-
CMs at day 60 post differentiation, the majority of RBM20-iPSC-CMs
showed a punctate distribution of sarcomeric α-actinin, a major com-
ponent of the cardiac Z-disk, over the bulk of the total cellular area
(Fig. 2A). Quantitative analysis of the regularity of sarcomere organi-
zation from the images of single iPSC-CMs stained for α-actinin re-
vealed that RBM20-iPSC-CMs were with a significantly abnormal dis-
tribution of sarcomeric α-actinin compared to control-iPSC-CMs
(P < 0.001; Fig. 2B). This phenotype was consistently observed in two
different RBM20-iPSC lines, suggesting a homogeneous correlation to
the disease-causing S635A mutation. Furthermore, we analyzed the
sarcomeric cTNT structure in RBM20- and control-iPSC-CMs (Fig. 2A)
and found only a slight difference between RBM20- and control-iPSC-
CMs (data not shown). Notably, when cell surface area was measured,
Fig. 2. RBM20-iPSC-CMs exhibited an abnormal distribu-
tion of sarcomeric α-actinin. A, immunostaining of sarco-
meric α-actinin, cTNT, MLC2A, and MLC2V in iPSC-CMs
two months post differentiation. Single RBM20-iPSC-CMs
exhibited punctate pattern of sarcomeric α-actinin sug-
gesting a disorganized myofilament structure compared to
control-iPSC-CMs (scale bars, 50 μm). No or low difference
in sarcomeric assembly was detected by using antibodies
against MLC2V, MLC2A, and cTNT, respectively (scale bars,
25 μm). B, enlarged views of small areas of images showing
detailed pattern of α-actinin staining in the cells. Using fast
Fourier transformation, the striation associated periodic
signal amplitude represented by the first spatial frequency
was analyzed for both control- and RBM20-iPSC-CMs. Bar
graphs summarize the first-order peak amplitude at the
spatial frequency. ***P < 0.001 RBM20 vs. control by
Student's t-test. C, no significant difference was observed in
cell surface between control- (n = 172 CMs from 5 differ-
entiation experiments using C1-1 and 1 experiment using
C3-1) and RBM20-iPSC-CMs (n = 117 CMs from 4 differ-
entiation experiments using 1-R-3 and 1 experiment using
1-R-7).
K. Streckfuss-Bömeke et al. Journal of Molecular and Cellular Cardiology 113 (2017) 9–21
13
no significant difference was observed between control- (n = 172 from
6 differentiation experiments) and RBM20-iPSC-CMs (n = 117 from 5
differentiation experiments) (Fig. 2C). These data suggest that RBM20-
iPSC-CMs could recapitulate disease phenotypes such as disturbed
sarcomere organization, as common in patients with DCM [22].
3.3. RBM20-iPSC-CMs exhibit defective calcium cycling
Defective Ca2+ cycling in CMs resulting in impaired muscle con-
tractility is a hallmark of cardiac dysfunction of patients with DCM. To
determine the functional consequence of RBM20 deficiency, we mea-
sured Ca2+ transients in both control- and RBM20-iPSC-CMs. The
spontaneously beating RBM20-iPSC-CMs, when compared to control-
iPSC-CMs, showed an increase in the peak amplitude of Ca2+ transients
with lower resting diastolic Ca2+ levels, but similar systolic Ca2+ levels
(Fig. 3A–D), indicating that more Ca2+ is released during each con-
traction-relaxation cycle in RBM20-iPSC-CMs. The rising time (time to
peak) was longer without altering the rising rate (Fig. 3E, F). However,
the Ca2+ transient decay rate (τ), mostly dependent on the activity of
Ca2+ reuptake by the sarcoplasmic reticulum, was significantly in-
creased in RBM20-iPSC-CMs compared with control-iPSC-CMs
(1.807 ± 0.25 s vs. 0.667 ± 0.20 s, P = 0.0002; Fig. 3G). Ad-
ditionally, an increase in the duration of Ca2+ transients was observed
in RBM20-iPSC-CMs compared with control-iPSC-CMs (Fig. 3H), in-
dicating defective calcium reuptake and cycling. In correlation with
these data, we also observed a significant larger area under the curve of
Ca2+ transients (Fig. 3I) and a lower frequency of Ca2+ transients in
RBM20-iPSC-CMs compared with control-iPSC-CMs (Fig. 3J).
3.4. Engineered heart muscles generated from RBM20-iPSC-CMs reveal
patient-specific RBM20 DCM phenotypes
Because patients with RBM20 mutations develop DCM, we asked
whether we could replicate the contractile pathophysiology of DCM in
an in vitro model of EHM generated from RBM20-iPSC-CMs (Video S2).
Consistent with the findings of cell surface area measured in the single
iPSC-CMs (Fig. 2C), the RBM20 mutation had no effect on the volume
(or size) of CMs in EHMs (data not shown). The amount of CMs (α-
actinin-positive cells) as muscle content after EHM generation was si-
milar in both RBM20- and control-EHMs (Fig. S3A). Cross sectional area
(CSA) of EHMs generated from RBM20-iPSC-CMs was also comparable
to control-EHMs (Fig. 4A). However, RBM20-EHMs showed an im-
paired force of contraction (FOC) in comparison to control-EHMs
(Figs. 4B, S3B). EHMs from both RBM20- and control-iPSC-CMs showed
a comparable inotropic response to β-adrenergic stimulation with iso-
prenaline (Fig. 4C). Interestingly, not only active force generation was
reduced in RBM20-EHMs (Fig. 4B), but also passive stress of the tissue
was decreased in response to stepwise increases in strain (Fig. 4D),
suggesting a higher visco-elasticity of RBM20-EHMs.
3.5. TTN alternative splicing is influenced during early development in
RBM20-iPSC-CMs
Titin normally undergoes a series of isoform expression changes
Fig. 3. RBM20-iPSC-CMs showed defective Ca2+ cycling.
Shown are representative Ca2+ tracings in spontaneously
beating control- and RBM20-iPSC-CMs (A), diastolic Ca2+
levels (B), systolic Ca2+ levels (C), peak amplitude of Ca2+
transients (D), time to peak (E), the rising slope (F), tran-
sient decay rate (τ, G), duration of Ca2+ transients (H),
average of the area under the curve of Ca2+ transients (I),
and frequency of Ca2+ transients (J). n = 28 CMs from 2
differentiation experiments using control-iPSC lines C1–1
and C1–2; n = 21 CMs from 2 differentiation experiments
using RBM20-iPSC lines 1-R-3 and 1-R-7. **P < 0.01;
***P < 0.001 RBM20 vs. control by Student's t-test.
K. Streckfuss-Bömeke et al. Journal of Molecular and Cellular Cardiology 113 (2017) 9–21
14
during development as a result of alternative splicing [23–25]. Previous
studies showed that the Rbm20 deletion in heterozygous or homo-
zygous rats alters the isoform expression of TTN, which is due to altered
TTN mRNA alternative splicing [2,24]. We studied here whether the
RBM20 mutation S635A has a similar effect on TTN alternative splicing
in iPSC-CMs. Primers were designed spanning exons 114-122 of TTN,
coding for part of the elastic PEVK region [3], to confirm the inclusion
of exons in TTN by RT-PCR. Our data revealed a significantly decreased
expression of the smaller products with 400 bp and 650 bp in RBM20-
iPSC-CMs compared to control-iPSC-CMs (Fig. 5A, S4A). The long
product (800 bp) with less exon skipping was used as internal control
(Figs. 5A, S4A). DNA-sequencing of the 400 bp band in control-iPSC-
CMs confirmed the expected short TTN isoform (data not shown). These
data indicate that the exon skipping in the PEVK region of TTN is re-
duced in RBM20-iPSC-CMs harboring the RBM20 mutation S635A.
3.6. The switch of TTN isoforms is inhibited in RBM20-iPSC-CMs
To determine whether the isoform switch of TTN is influenced by
the RBM20 mutation S635A, we analyzed the mRNA expression of titin
isoforms (Fig. 5B) and protein proportions (Fig. 6) in two-month-old
iPSC-CMs. Primers spanning exons 49 and 50 were designed to quantify
total cardiac TTN (N2B and N2BA) used as internal control since these
exons are constitutively expressed in both isoforms [26,27]. mRNA
Fig. 4. Functional phenotype of RBM20-EHMs. A, cross
sectional area (CSA) of EHMs from RBM20- and control-
iPSC-CMs. B, force of contraction per cross sectional area
(FOC/CSA) of EHMs in response to increasing extracellular
calcium concentration (0.2–4 mM) to assess the maximal
inotropic capacity of EHMs. C, inotropic response of EHMs
from RBM20- and control-iPSC-CMs to stimulation with
1 μM isoprenaline (Iso). D, stress-strain curve of EHMs from
RBM20- and control-iPSC-CMs. A-D: n = 13 control-EHMs
generated from 5 independent differentiation experiments
with control iPSC lines C1-1 and C3-1; n = 11 RBM20-
EHMs generated from 3 independent differentiation ex-
periments with RBM20-iPSC lines 1-R-2 and 1-R-3.
*P < 0.05 RBM20 vs. control by two-way ANOVA (B, D).
Fig. 5. TTN alternative splicing and isoform proportion are
affected in RBM20-iPSC-CMs. A, TTN alternative splicing is
influenced during early development in RBM20-iPSC-CMs.
RT-PCR analysis of RBM20- and control-iPSC-CMs at day 60
of differentiation and relative densitometry were performed
to detect the TTN alternative splicing variants with sizes of
250 bp, 400 bp, 650 bp, and 800 bp. The expression of TTN
short isoforms of 400 bp and 650 bp relative to the long
800 bp TTN isoform is significantly decreased in RBM20-
iPSC-CMs compared to control-iPSC-CMs. Primers (TTN-
Ex114-122) were designed to amplify TTN exons from 114
to 122. For RBM20-iPSC-CMs, n = 5 independent differ-
entiation experiments from 2 different cell lines 1-R-3 and
1-R-7 were analyzed. For control-iPSC-CMs, n = 8 in-
dependent differentiation experiments from 3 different cell
lines C1-1, C2-1 and C2-2 were studied. B, expression of the
TTN-N2B isoform is reduced and expression of the N2BA
variants are enhanced in RBM20-iPSC-CMs. Primers span-
ning TTN exons 49 and 50 (TTN-Ex49-50) were designed
for amplifying total TTN, which was used as internal con-
trol. For expression of N2B, a primer pair spanning exons
50 and 219 (TTN-N2B-Ex50-219) was used. For N2BA
variants, primers were designed spanning exons 50-51
(TTN-N2BA-Ex50-51) and 54-55 (TTN-N2BA-Ex54-55). The
same control- and RBM20-iPSC-CM samples were used as
shown in A. For RBM20-iPSC-CMs, n = 5 independent
differentiation experiments from 2 different cell lines 1-R-3
and 1-R-7 were analyzed. For control-iPSC-CMs, n= 7 in-
dependent differentiation experiments from 3 different cell lines C1-1, C2-1 and C2-2 were studied. *P < 0.05; **P < 0.01 RBM20 vs. control by Student's t-test.
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expression of the mature N2B isoform was analyzed by the use of a
primer pair spanning exons 50 and 219. We were able to show that
control-iPSC-CMs express the mature N2B isoform, which was calcu-
lated with 100%. However, TTN-N2B-mRNA was significantly reduced
in RBM20-iPSC-CMs (Figs. 5B, S4B). Two splicing variants (Ex50-51
and Ex54-55) of the N2BA isoform (estimated using primers spanning
exons 50-51 or 54-55) were also measured. In contrast to TTN-N2B
expression, expression of both Ex50-51 and Ex54-55 was significantly
increased to 122% (Ex50-51) and to 118% (Ex54-55) in RBM20-iPSC-
CMs compared to control-iPSC-CMs, respectively (Figs. 5B, S4B). These
results are consistent with protein expression of TTN isoforms in
RBM20- and control-iPSC-CMs. In control-iPSC-CMs, we showed the
expression of both TTN isoforms N2B and N2BA in 6 out of 6 different
experiments, similar to the pattern found in the heart tissue of healthy
individuals. In RBM20-iPSC-CMs (n = 4 differentiation experiments),
the mature N2B isoform was consistently less expressed (Fig. 6A).
Furthermore, we quantitatively analyzed the protein proportion of TTN
isoforms in RBM20-CMs and control-CMs (Fig. 6C). Healthy adult
human hearts express 60% to 70% N2B and 30% to 40% N2BA isoforms
[28]. In the human healthy heart tissue used in this study, 57% N2B and
43% N2BA TTN isoforms (n = 4 different gels analyzed) were ex-
pressed (Fig. 6C). In control-iPSC-CMs, we showed the expression of
TTN isoform N2B with 39% and N2BA with 61% (n = 6). This protein
proportion of TTN isoforms was impaired in RBM20-iPSC-CMs and the
expression of the N2B isoform was only 5.3% (n = 4) (Fig. 6C), sug-
gesting that the switch of TTN isoforms was inhibited in RBM20-iPSC-
CMs. These results were obtained by using different antibodies re-
cognizing the Z1-Z2 axis at the N-terminus of titin or the M-band at the
C-terminal part of titin (Fig. 6A).
3.7. Effects of the RBM20 mutation S635A on gene expression and
differential exon usage
We performed RNA-seq analysis to further assess RBM20-dependent
splicing and gene expression in iPSC-CMs. Comparison of transcriptome
profiles of control- and RBM20-iPSC-CMs revealed 161 differentially
expressed genes (DEGs; Fig. 7A, Table S3). RBM20 itself is not differ-
entially regulated in RBM20-iPSC-CMs compared to control-iPSC-CMs.
The 50 most regulated DEGs are shown in a heat map (Fig. 7B). In order
to estimate the inter-individual genetic variance and the effect it could
have on gene expression differences, we subjected the samples to
principal component analysis (PCA). As shown in Fig. 7C, the control
samples cluster together, while the disease samples form a clearly dis-
tinct cluster across the two dimensions shown. We therefore assume
that the main effect of the differential expression analysis results from
the disease genotype and not from inter-individual genotypic differ-
ences. GO enrichment analysis of DEGs identified genes with key
functions, including cellular components as stress fiber (MYLK, TEK,
UNC13D), negative regulation of protein depolymerization (FGF13,
MID1, SCIN, SHROOM2), drug metabolism (ADH1B, GSTT2, UGT2B15),
intercalated disc (DES, DSC2, DSG2, FGF13), glycosaminoglycan me-
tabolic process (BGN, CSGALNACT1, CYTL1, EGFLAM, FGF13, GPC3,
Fig. 6. Expression of cardiac TTN isoforms in RBM20-iPSC-
CMs. A, protein expression of TTN isoforms analyzed by
Western blot experiments using antibodies against the
Z1–Z2 domains at the NH2-terminus, and the M-band re-
gion at the COOH-terminus of titin, respectively. The anti-
body against Z-disk detects, in addition to the isoforms
N2BA and N2B, 1-2 lower-mass degradation bands con-
taining I-band of titin. The antibody against M-band de-
tects, in addition to the isoforms N2BA and N2B, the T2/
Cronos TTN products. Differentiated iPSC-CMs at day 60
from the RBM20 patient (1-R-3, 1-R-7), and control (C1-1,
C3-1) were used for analysis; shown are only two differ-
entiation experiments per condition. B, shown is the
Coomassie staining of a PVDF membrane before used for
Western blot as loading control. C, densitometry data
showing the decreased N2B protein proportion in RBM20-
iPSC-CMs (n = 4 independent differentiation from 2 cell
lines 1-R-3 and 1-R-7) in comparison to control-iPSC-CMs
(n = 6 independent differentiation from 2 cell lines C1-1
and C3-1). H indicates an adult human non-failing heart
included as a control (n = 4 technical replicates).
*P < 0.05 RBM20 vs. control by Student's t-test.
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GPC4, HS6ST2), or response to amino acids (COL4A6, CYP21A2,
DNMT3B, FOLR1, ICAM1, MMP3, MUC1) (Fig. 7D, Table S4).
High-throughput RNA-seq generates information on both gene and
exon level, allowing us analyzing our data with respect to differential
RBM20-dependent exon usage. We found 34 annotated genes with
significant changes in exon usage (DEEs) in RBM20-iPSC-CMs com-
pared to control-iPSC-CMs (Fig. 7A; Table S5). However, there was little
overlap between genes affected by altered splicing and genes that were
differentially expressed (Fig. 7A). In fact, only 2 out of the 161 DEGs
(FAM118A, HERC2P3) were differently spliced in RBM20-iPSC-CMs.
This data indicates that differential gene expression and alternative
splicing may affect different signaling pathways. To test this hypothesis,
we analyzed the differentially spliced genes for enrichment of
functional pathways. GO analysis of 34 genes with DEEs revealed that
there was a significant overrepresentation of genes associated with
ventricular cardiac muscle tissue development (MYH7, COL14A1),
myosin complex (MYH7, MYL7, MYOM1), ribosomal small subunit
biogenesis (RPS28, RPS6), virion assembly (DDX6, UBC), or regulation
of tumor necrosis factor-mediated signaling pathway (TNFRSF1A, UBC)
(Fig. 8A; Table S6). Of note, only few of these pathways were enriched
in gene-set of DEGs (Fig. 7D, Table S3). Vice versa, pathways linked to
metabolic processes, which dominated the list of DEGs (Fig. 7D), could
not be identified within the group of alternatively spliced genes
(Fig. 8A). These data suggest that metabolic responses in RBM20-iPSC-
CMs might be driven by changes in differential gene expression whereas
de-regulation of cardiac tissue development might be mainly attributed
Fig. 7. Modulation of gene expression in RBM20-iPSC-CMs. A, shown are the differentially expressed genes (DEGs) and exons (DEEs) in RBM20-iPSC-CMs compared to control-iPSC-CMs
illustrated in a Venn diagram. Only 2 genes were found to be differentially expressed on both gene and exon level. B, heat map of the 50 genes that are most differentially expressed
between control- and RBM20-CMs. C, PCA plot of control- and RBM20-iPSC-CM samples used for the analysis. D, significant enriched GO/Pathways in RBM20-iPSC-CMs compared to
control-iPSC-CMs according to ClueGo Cytoscape plugin. The data of differential expression are based on all up- or down-regulated genes. Data are generated by GO cellular component,
GO biological process or KEGG pathway analysis. Terms of same color correspond to terms containing similar group of genes. The bars represent the number of the genes from the
analyzed cluster found associated with the term, and the label displayed on the bars is the percentage of found genes compared to all the genes associated with the term. *P < 0.1;
**P < 0.05 calculated based on hypergeometric distribution from Database for annotation, visualization and integrated discovery (DAVID, v6.7). For control-iPSC-CMs, 6 independent
differentiation experiments from 2 cell lines of control 1 (C1-1, C1-2) and 2 cell lines from control 2 (C2-1, C2-2), and for RBM20-iPSC-CMs, 3 independent differentiation experiments
from 2 cell lines (1-R-2, 1-R-7) were analyzed.
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to differential splicing.
Furthermore, we validated some of the DEEs by RT-PCR analysis
(Fig. 8B). The downregulation of exon 2 in MYH7 in RBM20-iPSC-CMs,
as shown in DEE data (Fig. S5), was confirmed by the RT-PCR analysis
(Fig. 8B). MYH7 is the gene encoding the myosin heavy chain beta
isoform (β-MHC; Fig. S8A). The exclusion of exon 2 ofMYH7 in RBM20-
iPSC-CMs suggests a shift towards lower expression of β-MHC. β-MHC
plays a major role in cardiac muscle contraction and is specifically
implicated in the etiology of DCM, suggesting that RBM20-dependent
differential splicing events may be implicated with development of
dilative cardiac events.
COL14A1 encodes the alpha chain of type XIV collagen, which is
important for growth and structural integrity of the heart during em-
bryonic development [29]. RNA-seq data showed that exon 64 of
COL14A1 was differentially expressed in RBM20-iPSC-CMs compared to
control-iPSC-CMs (Table S5; Fig. S6). However, the differential ex-
pression of this exon was not confirmed by the RT-PCR analysis
(Fig. 8B). Exon 64 of COL14A1 is used for the expression of both iso-
forms 3 and 4 of COL14A1 (Fig. S8B).
Another DEE found in RNA-seq is exon 30 of FAM118A (Fig. S7),
which was also confirmed by the RT-PCR analysis, and is showing a
lower expression in RBM20-iPSC-CMs compared to control-iPSC-CMs
(Fig. 8B). Exon 30 of FAM118A is exclusively used by isoform 12 of
FAM118A (Fig. S8C), indicating the downregulation of this isoform in
RBM20-iPSC-CMs. GO annotations related to this gene include nucleic
acid binding. Interestingly, the DEG data revealed that the expression of
FAM118A was significantly lower in RBM20-iPSC-CMs as compared to
control-iPSC-CMs (Table S3).
For the gene OSGEP encoding O-sialoglycoprotein endopeptidase,
the RNA-seq data showed its exon 2 as DEE in RBM20-iPSC-CMs (Table
S5). The expression of this exon analyzed by RT-PCR showed a trend
towards downregulation in RBM20-iPSC-CMs compared to control-
iPSC-CMs, but this trend was not significant (Fig. 8B). Exon 2 of OSGEP
is exclusively used for the expression of protein coding isoform 1 of
OSGEP.
4. Discussion
In this study, we demonstrate the establishment of a human in vitro
DCM model by the use of iPSC-CMs from a DCM patient harboring the
RBM20 mutation S635A and present evidence that RBM20-iPSC-CMs
recapitulate abnormalities, such as cellular and molecular defects found
in individuals with RBM20-dependent DCM. We also provide RNA-seq
data, which may help us get insights into molecular mechanisms. Our
data revealed that the altered post-transcriptional modifications in
RBM20-iPSC-CMs might cause the RBM20-dependent DCM in the pa-
tient. Notably, by using RBM20-iPSC-CMs in comparison to control-
iPSC-CMs we were able to i) show a dysregulated sarcomeric organi-
zation and defective calcium handling in RBM20-iPSC-CMs; ii) identify
functional characteristics such as altered visco-elasticity and reduced
contractile force in RBM20-EHMs; iii) demonstrate an inhibition of TTN
alternative splicing and TTN isoform switch in RBM20-iPSC-CMs; and
iv) map transcriptome and splicing target profiles of RBM20-iPSC-CMs.
These structural and functional differences in iPSC-CMs and -EHMs
between control and the patient with the RBM20 mutation S635A are in
line with those found in rats with the Rbm20 deletion and in heart
biopsies taken from patients with the RBM20 mutations S635A or
P638L [2,4,9]. This indicates that human iPSC-CMs and -EHMs are
suitable model systems to study molecular and pathophysiological
mechanisms underlying RBM20-dependent DCM.
Fig. 8. Alternative splicing changes in RBM20-iPSC-CMs. A,
GO enrichment analysis of genes with DEEs reveals di-
vergent cellular pathways affected in RBM20-CMs when
compared to control, including ventricular cardiac muscle
tissue development, myosin complex, ribosomal small
subunit biogenesis and so on. Terms of same color corre-
spond to terms containing similar group of genes. The bars
represent the number of the genes from the analyzed cluster
found associated with the term, and the label displayed on
the bars is the percentage of found genes compared to all
the genes associated with the term. *P < 0.1; **P < 0.05
calculated based on hypergeometric distribution from
Database for annotation, visualization and integrated dis-
covery (DAVID, v6.7). B, differential expression of specific
exons with high adjusted P values as determined by RNA-
seq were confirmed by RT-PCR. *P < 0.05; **P < 0.01
RBM20 vs. control by Student's t-test.
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Our study adds to a recent report demonstrating the ability to model
RBM20 DCM using patient-specific iPSCs [30]. To our knowledge, this
is the first analysis up to now, where a RBM20-dependent DCM phe-
notype is modeled not only in a 2D monolayer but also in a 3D culture
for analysis of functionality. EHMs are more mature than 2D CMs albeit
not like in vivo heart muscles [18]. We observed the increased visco-
elasticity in RBM20-EHMs that implicates the diastolic function of the
heart in RBM20 DCM patients. Previous studies demonstrated that the
larger N2BA isoforms caused an increase in titin-based elasticity [16]
that has implications for diastolic function and the Frank-Starling me-
chanism [23,31]. In addition, an increased N2BA/N2B ratio in patients
with DCM was shown to correlate with a decreased passive stiffness of
cardiomyocytes [32,33]. In our study, we found a reduced active con-
tractile force generation and enhance visco-elasticity (reduced passive
tension) in RBM20-EHMs. Our findings are also in line with a study, in
which EHMs from iPSC-CMs with the TTN mutation W976R+/−
showed a similar phenotype with decreased active contractile force,
however, the visco-elasticity was not studied [34].
Importantly, we show for the first time that the mature TTN isoform
N2B was consistently less expressed in RBM20-iPSC-CMs on both RNA
and protein level. Although iPSC-CMs do not fully recapitulate the cell
biology of adult cardiomyocytes [35], we could show that control-iPSC-
CMs had a N2BA/N2B ratio of 61:39, nearing that in the adult human
heart, which was 43:57 in the present study. However, RBM20-iPSC-
CMs showed significant inhibition of the developmental titin-isoform
switch, with a N2BA/N2B ratio of 95:5. These data are consistent with
the data obtained from the RBM20 knockout rat showing that no N2B
isoform was detectable [23] and from the heart biopsy of patients with
the RBM20 mutations S635A [2] and E913K showing a shift from the
N2B to N2BA isoform [31]. This dramatic increase in TTN N2BA/N2B
ratio in RBM20-iPSC-CMs may be directly correlated with the inclusion
of exons in the PEVK regions.
RBM20 is predominantly expressed in striated muscle, most highly
in the heart, with transcript abundance 4-fold greater in cardiac than in
skeletal muscle [2,5]. RBM20 regulates the alternative splicing of a set
of genes including TTN as its most sensitive and prominent target [2].
Titin is a sarcomeric protein responsible for maintaining the structure
and biomechanical properties of muscle cells [28]. Many mutations in
TTN have been reported to be associated with DCM [36,37], and out of
them, at least 18 mutations are predicted to have an impact on TTN
splicing [38]. RBM20 regulates TTN alternative splicing by mediating
exon skipping in the elastic PEVK- and the immunoglobulin-rich regions
[3]. We observed that TTN alternative splicing was inhibited in RBM20-
iPSC-CMs with the RBM20 mutation S365A by analyzing the expression
of exons 114-122 in the PEVK regions (Figs. 5A, S4A). These data are in
line with those reported with patient heart biopsies [2,31]. Our data
point out an altered TTN alternative splicing already during early car-
diogenesis in the RBM20 DCM patient, confirming that RBM20-de-
pendent DCM is an early onset disorder patterned during early heart
development and propagated with pathological cardiac remodeling [9].
Taken together, our data demonstrate that altered TTN alternative
exon splicing in RBM20-iPSC-CMs may result in the reduced active
force generation and the increased visco-elasticity that implicate the
diastolic function of the heart in RBM20 DCM patients. The dis-
organized sarcomeric structures observed in RBM20-iPSC-CMs were
reported in previous studies using heart biopsies from patients with the
RBM20 mutation P638L or iPSC-CMs from patients with the RBM20
mutation R636S [9,30]. In addition, defective calcium cycling in
RBM20-iPSC-CMs were also reported in iPSC-CMs from patients with
the RBM20 mutation R636S [30]. These data suggest that the abnormal
pattern in sarcomere morphology and defective calcium handling ma-
chinery are common in RBM20-dependent DCM pathogenesis. This
could in part explain the anatomy and contractile dysfunction of the
dilated heart in RBM20 DCM patients.
Using RNA deep-sequencing, RBM20 was shown to be responsible
for different transcriptome profiles and involved in alternative splicing
of cardiac-specific genes [2,3]. Here, we show that RBM20-iPSC-CMs
can be used to detect a dysregulation of a variety of cardiac genes,
exons and pathways. We identified 161 DEGs and 34 genes with DEEs
in RBM20-iPSC-CMs (versus control). However, when we compare our
DEGs with the previous study using iPSC-CMs from patients with the
RBM20 mutation R636S [30], little overlap has been observed. One
explanation could be the profound differences in experimental ap-
proaches, where we used 60-day-old iPSC-CMs and Wyles et al. used
cells not older than 25 days implying the different maturation stages of
the cells used. Interestingly, while a large number of DEGs were found
in RNA-seq analysis, only 2 of these (FAM118A, HERC2P3) were asso-
ciated with altered splicing. Considering that RBM20 is thought to be
involved in regulating splicing, this raises the question why so many
genes are differentially expressed but not related to splicing. This could
be explained by that the splicing defect affects mainly titin, which is so
central to sarcomere integrity, and its disruption leads to multiple
secondary changes. Recently, the Seidman lab showed a large number
of genes (2237 genes) differentially expressed in 30–40-day old iPSC-
CMs carrying a truncated mutation in TTN (heterozygous, homozygous
N22577 fs) compared to control iPSC-CMs by RNA-seq [34]. However,
it is hard to compare these data with ours due to the different rationale
behind the studies (TTN alternative splicing vs. TTN truncation) and the
different experiment approaches (different ages of CMs used). Future
study could focus on direct comparing RBM20-iPSC-CMs with iPSC-CMs
generated from DCM patients with TTN mutations which have an im-
pact on TTN splicing only to figure out the primary and secondary gene
expression changes related to the RBM20 mutation.
When we analyzed gene and exon expression among the RBM20
group, the most affected pathways for DEGs are metabolic whereas,
interestingly, genes with DEEs are associated with cardiac muscle de-
velopment and myosin complex, including MYH7, MYL7, MYOM1 and
COL14A1. Both MYH7 and MYOM1 are directly bound by RBM20 and
are identified as direct targets of RBM20 for differential splicing [4].
Differential expression of exon 2 in MYH7 would suggest an altered
expression of β-MHC, which is expressed predominantly in normal
human ventricle. Changes in the relative abundance of β-MHC/α-MHC
correlate with the contractile velocity of cardiac muscle. These data
suggest that metabolic responses in the RBM20-defective CMs are
driven by changes in DEGs whereas de-regulation of cardiac tissue
development is mainly attributed to differential splicing. We noticed
that alternative splicing in some of the targets of RBM20, such as RYR2,
CAMK2D and LDB3, as shown in previous publications [2,4,24] has not
been identified in our DEE analysis. This might be due to the devel-
opmental stage and immature nature of iPSC-CMs. Using real-time PCR,
we currently investigate alternative splicing of these genes. Our pre-
liminary data showed that a 24-bp exon in RYR2 was upregulated in
RBM20-iPSC-CMs (our unpublished data), which is in line with the
published data shown in Rbm20-deficient rats and human cardiomyo-
pathy patients [4]. This 24-bp exon has profound effects on in-
tracellular Ca2+ signaling [39]. It is of paramount importance to in-
vestigate how RBM20 deficiency affects intracellular Ca2+ signaling,
which results in contractile deficits. Further studies are also needed to
identify more targets of RBM20 using iPSC-CMs.
A limitation of our study is that we have iPSC lines from only one
patient with the RBM20 mutation S635A. Since the genetic background
and sex of the RBM20 patient and controls can influence the results in
this work, isogenic control iPSCs (after correction of the RBM20 mu-
tation) would be ideal and should be used in future studies. Moreover,
studying other mutations in the RS-rich domain of RBM20 will validate
our findings and figure out the common pathomechanism for RBM20
DCM before development of future molecular diagnostic and ther-
apeutic approaches. Similar to other studies using iPSC-CMs and -EHMs
for disease modeling, another limitation of our study is the immature
phenotype of iPSC-CMs compared to their in vivo counterparts [40].
Furthermore, future studies should focus on the formation of a re-
producible tissue design with several cell types (e.g. CMs, fibroblasts
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and endothelial cells) organized in a way, which mimics human heart.
In conclusion, our studies using iPSC-CMs and -EHMs revealed that
the missense variant S635A in RBM20 causes sarcomeric disorganiza-
tion, defective calcium cycling, retention of the more compliant TTN
isoform, N2BA, and differential exon usages of genes related to cardiac
muscle function. Collectively, these may directly contribute to sub-
stantial contractile deficits. These findings indicate that patient-specific
2D iPSC-CMs coupled with 3D EHMs are suitable for modeling RBM20-
dependent DCM and provide robust functional genomic insights, which
might help to develop patient-specific therapeutic strategies in the fu-
ture.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.yjmcc.2017.09.008.
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